Physician profile
Rodolfo E Martinez
NPI 1184642282
$1,614.94
in general payments reported to CMS, 2019-2025
30 companies · $370 in 2025
The $370 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $671 · 2020: $199 · 2021: $97.71 · 2022: $29.08 · 2023: $37.21 · 2024: $210 · 2025: $370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $581 · Education: $37.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $580.62 |
| Education | $37.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $268.70 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $202.55 | 2019-2025 | Calquence, Imfinzi, Lynparza |
| Jazz Pharmaceuticals INC. | $106.19 | 2019-2025 | |
| Pfizer INC. | $97.79 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $95.50 | 2019-2021 | |
| Seagen INC. | $91.42 | 2019-2020 | |
| Abbvie INC. | $82.65 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $62.88 | 2019-2023 | Abecma |
| Genentech USA, INC. | $57.98 | 2019-2025 | Tecentriq, Tecentriq Hybreza, Columvi |
| Janssen Biotech, INC. | $51.90 | 2020-2025 | Tecvayli, Talvey, Darzalex |
| Daiichi Sankyo INC. | $48.63 | 2024-2025 | Enhertu |
| Eisai INC. | $44.52 | 2019-2020 | |
| Incyte Corporation | $41.87 | 2020-2025 | Jakafi |
| Amgen INC. | $36.33 | 2019-2020 | |
| Astellas Pharma US INC | $30.41 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $29.30 | 2025 | Xalkori, Braftovi, Lorbrena |
| Adaptive Biotechnologies Corporation | $27.91 | 2024 | Clonoseq |
| Genzyme Corporation | $26.66 | 2019 | |
| Celgene Corporation | $24.98 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $24.03 | 2025 | Onivyde |
| Rigel Pharmaceuticals, INC. | $23.81 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.78 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $17.35 | 2019 | |
| Dova Pharmaceuticals | $17.30 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $16.31 | 2019 | |
| Lilly USA, LLC | $15.88 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.37 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $13.05 | 2019 | |
| Acrotech Biopharma INC. | $11.97 | 2022 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodolfo Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.